Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 76 Polycystic Ovary Syndrome 3 Neoplasms, Hormone-Dependent 3 Neoplasm Metastasis 3 Arthralgia 3 Advanced Breast Cancer 3 Osteoporosis 2 Fractures, Bone 2 Endometrial Neoplasms 2 Carcinoma, Lobular 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Ductal, Breast 2 Breast Diseases 2 Breast Cancer Female 2 Sexuality 1 Sexual Dysfunctions, Psychological 1 Neurotoxicity Syndromes 1 Luminal B/HER2-negative Breast Cancer 1 Leiomyoma 1 Infertility 1 Hot Flashes 1 Hormone-receptor-positive Breast Cancer 1 Hormone Receptor Positive Breast Carcinoma 1 Hormone Receptor Positive Advanced Breast Cancer 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 HR+/HER2- Early Breast Cancer 1 HR+/HER2+ Early Breast Cancer 1 Fatigue 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Endometrial Stromal Tumors 1

Interventions

Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Early Breast Cancer × Aromatase Inhibitors × Clear all

NCT07616453 2026-06-01

TAYLOR-002

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting

HR+/HER2- Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡